News for Amgen Inc. (AMGN.BA)

Wall Street optimistic for July 4 weekend, sees opportunities in Freeport-McMoRan, Honeywell, Caterpillar, and Amgen. Analysts raise targets.

Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

Amgen Inc. (NASDAQ:AMGN) is one of the 11 stocks Jim Cramer put under the microscope recently. Cramer highlighted Wall Street’s reaction to the company’s latest data announcement regarding MariTide, and said: “Unlike Mounjaro or Ozempic, which needed to be injected once a week, Amgen’s MariTide is one shot per month. I prefer monthly over weekly […]

Microsoft is struggling to sell its Copilot AI assistant to corporations because many of their employees want ChatGPT.

Microsoft is struggling to sell its Copilot AI assistant to corporations because many of their employees want ChatGPT.

Amgen Inc. (NASDAQ:AMGN) Special Call (IR Call) Conference June 23, 2025 5:30 PM ETCompany ParticipantsJustin Claeys - Vice President of Investor Relations...

Amgen's new treatment, MariTide, shows promising weight loss results. Despite positive trial outcomes, AMGN shares saw a 6% dip. Analysts predict a potenti

Amgen (AMGN) shares dropped by $14.58, or 5%, reaching $274.75 in the afternoon trading session. This decline followed the company's announcement of detailed re

A heated debate over the U.S. healthcare system erupted on X, pitting billionaire entrepreneur Mark Cuban against Sen. Elizabeth Warren (D-Mass) over the root causes of soaring drug prices. What Happened: The clash, unfolding as of Friday, has ...

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Amgen Inc. (NASDAQ:AMGN) Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 9:20 PM ETCompany ParticipantsJames E.

Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.

Amgen Q1 2025 results beat estimates with strong product growth. Stay updated on tariff risks and drug pricing impacts.

Amgen Inc.

Amgen's Breakthrough: Interim results from Amgen's Phase III trial show Imdelltra significantly improving survival rates in small cell lung cancer. Anal

Summary Amgen Inc (AMGN) has announced promising interim results from its global Phase 3 DeLLphi-304 trial, revealing that IMDELLTRA® (tarlatamab-dlle) signifi

Amgen (AMGN) has revealed promising interim findings from its global Phase 3 DeLLphi-304 study. The trial demonstrated that IMDELLTRA significantly lowered the

**media[642718]**